A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Cystic FibrosisExocrine Pancreatic Insufficiency
Interventions
DRUG

EUR-1008 (APT-1008)

EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.

DRUG

EUR-1008 (APT-1008)

EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.

Trial Locations (6)

17033

Penn State Milton S. Hershey Medical Center, Hershey

32250

Nemours Children's Clinic, Jacksonville

44308

Akron Children's Hospital, Akron

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

Cystic Fibrosis Care Center, Houston

89107

Children's Lung Specialists Ltd., Las Vegas

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY